Research ExplorerPublicationsEffect of Neoadjuvant Chemotherapy on Complications, in-Hosp...

Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy

Standard

Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy. / Hoeh, Benedikt; Flammia, Rocco Simone; Hohenhorst, Lukas; Sorce, Gabriele; Chierigo, Francesco; Panunzio, Andrea; Tian, Zhe; Saad, Fred; Gallucci, Michele; Briganti, Alberto; Terrone, Carlo; Shariat, Shahrokh F; Graefen, Markus; Tilki, Derya; Antonelli, Alessandro; Kluth, Luis A; Mandel, Philipp; Chun, Felix K H; Karakiewicz, Pierre I.

In: CANCERS, Vol. 14, No. 5, 1222, 26.02.2022.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hoeh, B, Flammia, RS, Hohenhorst, L, Sorce, G, Chierigo, F, Panunzio, A, Tian, Z, Saad, F, Gallucci, M, Briganti, A, Terrone, C, Shariat, SF, Graefen, M, Tilki, D, Antonelli, A, Kluth, LA, Mandel, P, Chun, FKH & Karakiewicz, PI 2022, 'Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy', CANCERS, vol. 14, no. 5, 1222. https://doi.org/10.3390/cancers14051222

APA

Hoeh, B., Flammia, R. S., Hohenhorst, L., Sorce, G., Chierigo, F., Panunzio, A., Tian, Z., Saad, F., Gallucci, M., Briganti, A., Terrone, C., Shariat, S. F., Graefen, M., Tilki, D., Antonelli, A., Kluth, L. A., Mandel, P., Chun, F. K. H., & Karakiewicz, P. I. (2022). Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy. CANCERS, 14(5), [1222]. https://doi.org/10.3390/cancers14051222

Vancouver

Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Chierigo F, Panunzio A et al. Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy. CANCERS. 2022 Feb 26;14(5). 1222. https://doi.org/10.3390/cancers14051222

Bibtex

@article{4c020112664948309531afc6ae6597b1,
title = "Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy",
abstract = "Background: To test for differences in complication rates, in-hospital mortality, length of stay (LOS) and total hospital costs (THCs) in patients treated with neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC). Methods: Within the National (Nationwide) Inpatient Sample (NIS) database (2016−2019), we identified RC-treated, non-metastatic, lymph-node negative bladder cancer patients, stratified by NAC status. Trend analyses, multivariable logistic, multivariable Poisson and multivariable linear regression models were used. Results: We identified 4347 RC-treated bladder cancer patients. Of those, 805 (19%) received NAC prior to RC. Overall, complications rates did not differ (65 vs. 66%; p = 0.7). However, NAC patients harbored lower rates of surgical site (6 vs. 9%), cardiac (13 vs. 19%) and genitourinary (5.5 vs. 9.7%) complications. In-hospital mortality (<1.7 vs. 1.8%) and LOS (6 vs. 7 days) was lower in NAC patients (all p < 0.05). Moreover, NAC was an independent predictor of shorter LOS in multivariable Poisson regression models (Risk ratio: 0.86; p < 0.001) and an independent predictor for higher THCs in multivariable linear regression models (Odds ratio: 1474$; p = 0.02). Conclusion: NAC was not associated with higher complication rates and in-hospital mortality. Contrary, NAC was associated with shorter LOS, yet moderately higher THCs. The current analysis suggests no detriment from NAC in the context of RC.",
author = "Benedikt Hoeh and Flammia, {Rocco Simone} and Lukas Hohenhorst and Gabriele Sorce and Francesco Chierigo and Andrea Panunzio and Zhe Tian and Fred Saad and Michele Gallucci and Alberto Briganti and Carlo Terrone and Shariat, {Shahrokh F} and Markus Graefen and Derya Tilki and Alessandro Antonelli and Kluth, {Luis A} and Philipp Mandel and Chun, {Felix K H} and Karakiewicz, {Pierre I}",
year = "2022",
month = feb,
day = "26",
doi = "10.3390/cancers14051222",
language = "English",
volume = "14",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "5",

}

RIS

TY - JOUR

T1 - Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy

AU - Hoeh, Benedikt

AU - Flammia, Rocco Simone

AU - Hohenhorst, Lukas

AU - Sorce, Gabriele

AU - Chierigo, Francesco

AU - Panunzio, Andrea

AU - Tian, Zhe

AU - Saad, Fred

AU - Gallucci, Michele

AU - Briganti, Alberto

AU - Terrone, Carlo

AU - Shariat, Shahrokh F

AU - Graefen, Markus

AU - Tilki, Derya

AU - Antonelli, Alessandro

AU - Kluth, Luis A

AU - Mandel, Philipp

AU - Chun, Felix K H

AU - Karakiewicz, Pierre I

PY - 2022/2/26

Y1 - 2022/2/26

N2 - Background: To test for differences in complication rates, in-hospital mortality, length of stay (LOS) and total hospital costs (THCs) in patients treated with neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC). Methods: Within the National (Nationwide) Inpatient Sample (NIS) database (2016−2019), we identified RC-treated, non-metastatic, lymph-node negative bladder cancer patients, stratified by NAC status. Trend analyses, multivariable logistic, multivariable Poisson and multivariable linear regression models were used. Results: We identified 4347 RC-treated bladder cancer patients. Of those, 805 (19%) received NAC prior to RC. Overall, complications rates did not differ (65 vs. 66%; p = 0.7). However, NAC patients harbored lower rates of surgical site (6 vs. 9%), cardiac (13 vs. 19%) and genitourinary (5.5 vs. 9.7%) complications. In-hospital mortality (<1.7 vs. 1.8%) and LOS (6 vs. 7 days) was lower in NAC patients (all p < 0.05). Moreover, NAC was an independent predictor of shorter LOS in multivariable Poisson regression models (Risk ratio: 0.86; p < 0.001) and an independent predictor for higher THCs in multivariable linear regression models (Odds ratio: 1474$; p = 0.02). Conclusion: NAC was not associated with higher complication rates and in-hospital mortality. Contrary, NAC was associated with shorter LOS, yet moderately higher THCs. The current analysis suggests no detriment from NAC in the context of RC.

AB - Background: To test for differences in complication rates, in-hospital mortality, length of stay (LOS) and total hospital costs (THCs) in patients treated with neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC). Methods: Within the National (Nationwide) Inpatient Sample (NIS) database (2016−2019), we identified RC-treated, non-metastatic, lymph-node negative bladder cancer patients, stratified by NAC status. Trend analyses, multivariable logistic, multivariable Poisson and multivariable linear regression models were used. Results: We identified 4347 RC-treated bladder cancer patients. Of those, 805 (19%) received NAC prior to RC. Overall, complications rates did not differ (65 vs. 66%; p = 0.7). However, NAC patients harbored lower rates of surgical site (6 vs. 9%), cardiac (13 vs. 19%) and genitourinary (5.5 vs. 9.7%) complications. In-hospital mortality (<1.7 vs. 1.8%) and LOS (6 vs. 7 days) was lower in NAC patients (all p < 0.05). Moreover, NAC was an independent predictor of shorter LOS in multivariable Poisson regression models (Risk ratio: 0.86; p < 0.001) and an independent predictor for higher THCs in multivariable linear regression models (Odds ratio: 1474$; p = 0.02). Conclusion: NAC was not associated with higher complication rates and in-hospital mortality. Contrary, NAC was associated with shorter LOS, yet moderately higher THCs. The current analysis suggests no detriment from NAC in the context of RC.

U2 - 10.3390/cancers14051222

DO - 10.3390/cancers14051222

M3 - SCORING: Journal article

C2 - 35267529

VL - 14

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 5

M1 - 1222

ER -